A novel oncogenic driver in Ewing sarcoma
A novel oncogenic driver in Ewing sarcoma
批准号:
9321922
负责人:
YUZURU SHIIO
金额:
$16.58万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-27 至 2019-06-30
关键词:
AddressBindingBiologicalBone TissueCapersCell LineCellsCharacteristicsChildChromosomal translocationChromosomesClinicalCloningDataDevelopmentDiseaseEWS-FLI1 fusion proteinEwings sarcomaFailureFamilyFutureGene ExpressionGeneticGrowthHumanImpairmentInvestigationLightMalignant Bone NeoplasmMesenchymal Stem CellsModelingMusMutationNorthern BlottingOncogenesOncogenicOther GeneticsOutcomePathogenesisPhasePhenotypePlayProtein IsoformsPublic HealthRNA SplicingRecurrenceResearchRoleSamplingTP53 geneTestingToxic effectTransgenic MiceTumor AngiogenesisTumorigenicityVascular Endothelial Growth Factorscell typedisease phenotypefusion genegenome sequencingknock-downmouse modelnovelnovel therapeutic interventionprotein protein interactionsoft tissuetargeted treatmenttranscription factortumor
中文摘要
这个探索性项目旨在了解一种新的致癌驱动因子的生物学作用
英文摘要
This exploratory project is directed towards understanding the biological role of a novel oncogenic driver in
Ewing sarcoma. Ewing sarcoma is an aggressive cancer of bone and soft tissues in children with poor long-
term outcome. It is characterized by the chromosomal translocation generating a fusion oncogene between
EWS and an Ets family transcription factor, most commonly FLI-1. EWS-FLI-1 translocation accounts for 85%
of Ewing sarcoma cases.
Since the cloning of the EWS-FLI-1 fusion oncogene, the predominant view in the Ewing sarcoma field
has been that EWS-FLI-1 plays a central role in Ewing sarcomagenesis. EWS-FLI-1 is able to transform
mouse cells such as NIH3T3 and C3H10T1/2 and the knockdown of EWS-FLI-1 inhibits the survival,
proliferation and tumorigenicity of Ewing sarcoma cells, suggesting that EWS-FLI-1 is the causative oncogene.
However, a variety of evidence also suggest that EWS-FLI-1 alone cannot fully explain the Ewing
sarcomagenesis: 1) EWS-FLI-1 alone cannot transform any human cell types including human mesenchymal
stem cells which are the putative cells of origin of Ewing sarcoma; 2) Generating a transgenic mouse model of
Ewing sarcoma by using EWS-FLI-1 alone has been unsuccessful; and 3) Other genetic alterations such as
mutations of INK4a and p53 confer worse clinical outcome.
The applicant's group has identified a novel oncogenic driver for Ewing sarcoma, which is required for
Ewing sarcoma proliferation and which cooperates with EWS-FLI-1 in mesenchymal stem cells. This project
will address the biological role of this novel oncogenic driver in Ewing sarcoma by pursuing the following two
specific aims: 1) Delineate its role in established Ewing sarcoma and 2) Modelling Ewing sarcoma by co-
expression with EWS-FLI-1.
The proposed research has the potential to shed new light on the long-standing conundrums in the
Ewing sarcoma field such as the inability of EWS-FLI-1 to transform any human cell types, the failure to
develop a genetic mouse model of Ewing sarcoma using EWS-FLI-1 alone, and the lack of a targeted therapy
for Ewing sarcoma.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
The role of the receptor complex and the cofactors in IGSF10 signaling
-
批准号:10728450
-
项目类别:
-
资助金额:$35.46万
-
财政年份:2023
-
负责人:YUZURU SHIIO
-
依托单位:
A novel oncogenic driver in Ewing sarcoma
-
批准号:9179478
-
项目类别:
-
资助金额:$19.9万
-
财政年份:2016
-
负责人:YUZURU SHIIO
-
依托单位:
Secretome Proteomics for VHL Tumor Biomarker Discovery
-
批准号:7740299
-
项目类别:
-
资助金额:$16.33万
-
财政年份:2009
-
负责人:YUZURU SHIIO
-
依托单位:
Quantitative Proteomic Analysis of the Secretory Pattern of Senescent Cells
-
批准号:7187525
-
项目类别:
-
资助金额:$14.97万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Analysis of the VHL-HIF hydroxylase pathway
-
批准号:7314758
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Analysis of the VHL-HIF hydroxylase pathway
-
批准号:7500280
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Analysis of the VHL-HIF hydroxylase pathway
-
批准号:7669079
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Quantitative Proteomic Analysis of the Secretory Pattern of Senescent Cells
-
批准号:7348336
-
项目类别:
-
资助金额:$14.67万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Analysis of the VHL-HIF hydroxylase pathway
-
批准号:8100114
-
项目类别:
-
资助金额:$21.53万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Analysis of the VHL-HIF hydroxylase pathway
-
批准号:7896480
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: